Frequency Therapeutics logo
Frequency Therapeutics FREQ

Annual report 2025
added 03-12-2026

report update icon

Frequency Therapeutics General and Administrative Expenses 2011-2026 | FREQ

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.
What these expenses include
  • Salaries of administrative staff (executives, HR, accountants, legal personnel)
  • Office rent and utilities
  • Office equipment and IT infrastructure
  • Professional services (auditors, lawyers, consultants)
  • Insurance
  • General administrative travel and representation expenses
What the metric indicates
  • Cost control
    A high level of such expenses may indicate inefficient management or an overly complex structure
  • Profitability
    Reducing administrative expenses while maintaining stable revenue increases operating profit
  • Comparative analysis
    Investors can compare this metric as a percentage of revenue among companies in the same industry
  • Business flexibility
    Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Frequency Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
28.2 M 30.5 M 27.3 M 16.8 M 37.2 M 27.1 M 30.8 M 7.06 M 4.34 M - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
37.2 M 4.34 M 23.3 M

Quarterly General and Administrative Expenses Frequency Therapeutics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
6.51 M 7.63 M 7.83 M - 7.33 M 6.99 M 7.88 M - 5.14 M 5.28 M 5.39 M - 8.56 M 8 M 9.48 M - 9.33 M 9.5 M 9.74 M - 6.51 M 5.96 M 6.25 M - 4.27 M 3.1 M 2.47 M - 1.51 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
9.74 M 1.51 M 6.58 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer General and Administrative Expenses Price % 24h Market Cap Country
BioLineRx Ltd. BioLineRx Ltd.
BLRX
4.31 M $ 2.25 1.81 % $ 908 M israelIsrael
BioNTech SE BioNTech SE
BNTX
286 M $ 91.28 0.11 % $ 27.2 B germanyGermany
MorphoSys AG MorphoSys AG
MOR
78.3 M - 2.43 % $ 254 M germanyGermany
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
1.21 B $ 330.34 3.6 % $ 43.3 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
5.94 M $ 0.44 -16.64 % $ 5.04 M israelIsrael
I-Mab I-Mab
IMAB
900 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
1.4 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
16.2 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
7.15 M - -13.47 % $ 169 M franceFrance
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
63.1 M $ 24.98 1.17 % $ 3.05 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
4.95 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
4.66 M - -1.52 % $ 24.7 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
15.2 M $ 10.14 -0.29 % $ 135 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
14.2 M $ 1.58 - $ 106 M usaUSA
Curis Curis
CRIS
14 M $ 0.53 -3.07 % $ 6.98 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
89.7 M - -24.86 % $ 820 K usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
191 M $ 37.7 1.26 % $ 3.55 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
73.5 M $ 49.15 -0.73 % $ 4.42 B schweizSchweiz
Adverum Biotechnologies Adverum Biotechnologies
ADVM
63.1 M - - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
12.2 M - -9.65 % $ 45.9 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
13.8 M $ 2.96 -1.0 % $ 252 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
37.4 M - - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
5.92 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
11 M - -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
23.8 M - 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
47.9 M - - $ 1.01 B usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
29.8 M $ 4.4 -3.51 % $ 607 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
17 M - - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
37.9 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
22.2 M - 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
25.8 M - - - russiaRussia
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
18.2 M $ 0.86 0.67 % $ 5.79 M usaUSA
Cue Biopharma Cue Biopharma
CUE
16.2 M $ 0.18 -1.61 % $ 17.1 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
12.7 M - 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
18 M - - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
10.9 M - 10.36 % $ 9.8 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
79.8 M $ 4.09 -0.97 % $ 437 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
5.34 M $ 4.15 -32.52 % $ 10.4 M usaUSA
Daré Bioscience Daré Bioscience
DARE
8.76 M $ 1.81 4.02 % $ 20.2 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
32.8 M $ 20.36 -3.32 % $ 2.84 B franceFrance
Aravive Aravive
ARAV
13 M - -13.39 % $ 1.45 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
46.1 M $ 8.22 2.37 % $ 225 M israelIsrael
Aptose Biosciences Aptose Biosciences
APTO
13.4 M - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
19.8 M - -39.0 % $ 4.57 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
105 M $ 19.38 -6.15 % $ 3.19 B usaUSA
Dyadic International Dyadic International
DYAI
890 K $ 0.87 -2.8 % $ 31.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
100 M - - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
15.2 B - - $ 96.9 B britainBritain
Celldex Therapeutics Celldex Therapeutics
CLDX
43.8 M $ 31.37 1.0 % $ 2.08 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
3.65 M - -52.27 % $ 4.45 M usaUSA